Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Jul 25, 2014 8:44am
232 Views
Post# 22781195

RE:RE:RE:RE:Where We Are Now

RE:RE:RE:RE:Where We Are NowGood point Storm23.

Don has obviously been very busy getting the financing, hiring a Zenith CEO, etc. By hiring the new Zenith CEO it achieves a few important things;
  1. It brings a high degree of credibility to the Zenith brand. She would not have taken the job unless she believes in the potential.
  2. It brings in a person with excellent scientific depth and knowledge as well as a large network within the BP industry.
  3. In brings in a person with significant business experience and importantly a track record of achieving drug approvals with the FDA.
  4. A person capable of managing the IPO structures and roll outs.
  5. It frees up Don's time to focus all of his attention on RVX in terms of continuing to make connections with BP in order to set the groundwork for a possible sale.
  6. Don should be able to dedicate some time to shareholder value.
  7. AND, hahaha, it frees up Don's time to hire a competent communications expert so that the kind of failure that occurred on the communications of the diabetes trial results never happens again.
Let's hope the action and pace increases. I would assume that RVX has been  working on the ph2c trial design for at least the past 8 months and it that it should fall into place immediately at or before the financing vote (given that the financing will definitely be approved).

There's too many good things happening. I guess it will all depend on the trial. GLTA.
Cheers
Toinv


Bullboard Posts